Anthrax immune globulin - Emergent BioSolutions (Cangene)Alternative Names: AIGIV; Anthrasil; Anthrax immune globulin - Cangene; Anthrax immune globulin intravenous; NP-015
Latest Information Update: 04 Dec 2015
At a glance
- Originator Cangene Corporation
- Developer Emergent BioSolutions
- Class Immunoglobulins; Monoclonal antibodies; Polyclonal antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Anthrax